Ercaliskan, A., & Eskazan, A. E. (2018). The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer (0008543X), 124(19), 3806-3819.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Ercaliskan, Abdulkadir, y A. Emre Eskazan. "The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia."
Cancer (0008543X) 124, no. 19 (2018): 3806-3819.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Ercaliskan, Abdulkadir, y A. Emre Eskazan. "The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia."
Cancer (0008543X), vol. 124, no. 19, 2018, pp. 3806-3819.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.